Bergen, 14 May 2006: In accordance with the Power of Attorney given at the extraordinary general meeting on 31 January 2006, and as informed in the stock exchange notification on the same date, the Board of NorDiag ASA has completed a distribution of 120 000 options in an optional program for the management and the employees of the company.

The option has a term of 3 years, where up to 1/3 can be cashed every year. Strike price for the options is NOK 13 per share.

Of the above mentioned, the following amount was allotted to the management team and the primary insiders (new stock of shares and options are given in brackets); Primary insider Dr. Jochen Felbel has been alloted 100 000 options (17 345 shares, 100 000 options).

Dr Jochen Felbel is connected to NorDiag on a consultancy basis as Medical Director for the company. Dr Jochen Felbel is currently Medical Director of Abbott MediSense Europe, Middle East and Africa, and has experience in developing trial protocols and from commercial business development and licensing. Dr. Felbel`s academic achievements include an MD, two Ph.D.`s and an MBA in the Medical and Business fields. Dr. Felbel is a German citizen and resides in Wiesbaden, Germany.

The Board has a Power of Attorney to assign up to 1 880 494 options in the company (8% of outstanding shares), and has after today`s assignment a spare pot of 260 594 options that will be used in an optional program for new employees and key personnel of the company.

Bergen, 14 May 2006
The Board of NorDiag ASA